CY1124717T1 - Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων - Google Patents
Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρωνInfo
- Publication number
- CY1124717T1 CY1124717T1 CY20211100943T CY211100943T CY1124717T1 CY 1124717 T1 CY1124717 T1 CY 1124717T1 CY 20211100943 T CY20211100943 T CY 20211100943T CY 211100943 T CY211100943 T CY 211100943T CY 1124717 T1 CY1124717 T1 CY 1124717T1
- Authority
- CY
- Cyprus
- Prior art keywords
- kits
- cells
- provides
- expansion
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract 3
- 238000006116 polymerization reaction Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Sustainable Development (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Computer Hardware Design (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε in vitro μεθόδους επέκτασης πληθυσμού κυττάρων όπως λεμφοκυττάρων, οι οποίες περιλαμβάνουν επαφή ενός δείγματος που περιλαμβάνει έναν πληθυσμό κυττάρων με ένα αντιδραστήριο πολυμερισμού. Το αντιδραστήριο πολυμερισμού έχει αναστρέψιμα ακινητοποιημένο σε αυτό (προσδεδεμένο σε αυτό) έναν πρώτο παράγοντα που παρέχει ένα πρωτεύον σήμα ενεργοποίησης προς τα κύτταρα και προαιρετικά, έναν δεύτερο παράγοντα που παρέχει ένα συν-διεγερτικό σήμα. Η εφεύρεση επίσης παρέχει αντιδραστήρια πολυμερισμού, κιτ, διατάξεις και μία συσκευή για επέκταση κυττάρων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461980506P | 2014-04-16 | 2014-04-16 | |
PCT/EP2015/058339 WO2015158868A2 (en) | 2014-04-16 | 2015-04-16 | Methods, kits and apparatus for expanding a population of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124717T1 true CY1124717T1 (el) | 2022-07-22 |
Family
ID=53052805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100943T CY1124717T1 (el) | 2014-04-16 | 2021-11-02 | Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων |
Country Status (26)
Country | Link |
---|---|
US (2) | US11274278B2 (el) |
EP (2) | EP3988920A1 (el) |
JP (3) | JP6696969B2 (el) |
KR (2) | KR20220150988A (el) |
CN (3) | CN116656605A (el) |
AU (2) | AU2015248786B2 (el) |
BR (1) | BR112016024072B1 (el) |
CA (2) | CA3176848A1 (el) |
CY (1) | CY1124717T1 (el) |
DK (1) | DK3132247T3 (el) |
ES (1) | ES2892927T3 (el) |
HR (1) | HRP20211430T1 (el) |
HU (1) | HUE056852T2 (el) |
IL (3) | IL293587A (el) |
LT (1) | LT3132247T (el) |
MX (2) | MX2016013493A (el) |
MY (1) | MY184699A (el) |
PH (2) | PH12016502017B1 (el) |
PL (1) | PL3132247T3 (el) |
PT (1) | PT3132247T (el) |
RS (1) | RS62471B1 (el) |
RU (2) | RU2735640C9 (el) |
SA (1) | SA516380090B1 (el) |
SG (2) | SG11201608557UA (el) |
SI (1) | SI3132247T1 (el) |
WO (1) | WO2015158868A2 (el) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10228312B2 (en) | 2012-02-23 | 2019-03-12 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
SG11201608557UA (en) * | 2014-04-16 | 2016-11-29 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
ES2759260T3 (es) | 2014-04-23 | 2020-05-08 | Juno Therapeutics Inc | Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
MA45488A (fr) * | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
BR112018008111A2 (pt) | 2015-10-22 | 2018-11-06 | Juno Therapeutics Gmbh | métodos, kits, agentes e aparelhos para transdução |
EP3192810A1 (en) | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
CN107129988A (zh) * | 2016-02-29 | 2017-09-05 | 广西医科大学 | 一种特异性结合cd3的核酸适配体及其筛选方法和应用 |
KR20230125857A (ko) * | 2016-06-02 | 2023-08-29 | 클로토 테라퓨틱스, 아이엔씨. | 치료학적 재조합 클로토 단백질 및 이를 수반하는 조성물및 방법 |
AU2017301887A1 (en) | 2016-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies against anti-CD19 antibodies |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
KR20190098747A (ko) * | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
US20210047602A1 (en) * | 2017-03-31 | 2021-02-18 | Terumo Bct, Inc. | Cell expansion |
US11624046B2 (en) * | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (en) * | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
MA49288A (fr) * | 2017-04-27 | 2020-03-04 | Juno Therapeutics Gmbh | Reactifs particulaires oligomères et leurs méthodes d'utilisation |
WO2019118918A1 (en) * | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
CN107904278B (zh) * | 2017-12-25 | 2021-07-20 | 北昊干细胞与再生医学研究院有限公司 | 检测药物对细胞增殖影响的方法 |
US11149244B2 (en) * | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
CN112424342A (zh) * | 2018-05-08 | 2021-02-26 | 生命科技公司 | 用于培养和扩增细胞的组合物和方法 |
US20210206857A1 (en) * | 2018-05-21 | 2021-07-08 | Bioprocessia Technologies Llc | Multivalent protein complexes |
JP2021533746A (ja) | 2018-08-09 | 2021-12-09 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞およびその組成物を生成するための方法 |
EP3623383A1 (en) | 2018-09-11 | 2020-03-18 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved bispecific flt3xcd3 antigen binding proteins |
WO2020053300A1 (en) | 2018-09-11 | 2020-03-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved anti-flt3 antigen binding proteins |
KR20210064299A (ko) * | 2018-09-24 | 2021-06-02 | 사우스웨스트 리서치 인스티튜트 | 3d 생물반응기 |
JP2022512872A (ja) | 2018-10-31 | 2022-02-07 | ジュノ セラピューティクス ゲーエムベーハー | 細胞の選択および刺激のための方法ならびにそのための装置 |
KR20200132147A (ko) * | 2019-05-15 | 2020-11-25 | 의료법인 성광의료재단 | 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법 |
JP7304649B2 (ja) * | 2019-05-24 | 2023-07-07 | ソル バイオ コーポレーション | スイッチ性付着反応を用いた親和分離システム及び方法 |
MX2021015125A (es) * | 2019-06-07 | 2022-04-06 | Juno Therapeutics Inc | Cultivo automatizado de celulas t. |
JP2023500318A (ja) | 2019-10-30 | 2023-01-05 | ジュノ セラピューティクス ゲーエムベーハー | 細胞選択および/または細胞刺激デバイスならびに使用方法 |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
IL293430A (en) | 2019-12-06 | 2022-07-01 | Juno Therapeutics Inc | Anti-idiotic antibodies to bcma-targeted binding domains and related compositions and methods |
WO2021113780A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
US11965882B2 (en) | 2020-01-31 | 2024-04-23 | Cell.Copedia GmbH | Methods of isolating a biological entity |
CN115361955A (zh) | 2020-02-12 | 2022-11-18 | 朱诺治疗学股份有限公司 | 针对bcma的嵌合抗原受体t细胞组合物及其方法和用途 |
IL295384A (en) | 2020-02-12 | 2022-10-01 | Juno Therapeutics Inc | Preparations of t cells with a chimeric antigen receptor directed against cd19 and methods and uses thereof |
JP2023536326A (ja) | 2020-08-05 | 2023-08-24 | ジュノー セラピューティクス インコーポレイテッド | Ror1標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法 |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
WO2022204070A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
CN117957313A (zh) | 2021-07-19 | 2024-04-30 | 修复免疫股份有限公司 | 从多能干细胞生产免疫细胞群的方法 |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
DE3583940D1 (de) | 1984-10-02 | 1991-10-02 | Harry M Meade | Herstellung von streptavidinaehnlichen polypeptiden. |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
CA2164226C (en) | 1993-06-04 | 2011-02-08 | Carl H. June | Methods for selectively stimulating proliferation of t cells |
AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
JPH11501008A (ja) | 1995-02-09 | 1999-01-26 | ユニバーシティ オブ ワシントン | 改変−アフィニティーストレプトアビジン |
US6022951A (en) | 1995-04-11 | 2000-02-08 | Univ Boston | Streptavidin mutants |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
EP0977770A4 (en) | 1997-03-14 | 2000-04-05 | Univ Boston | DIFFERENTLY FLAVORED STREPTAVIDINE |
US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
WO2000043551A1 (en) | 1999-01-26 | 2000-07-27 | Cornell Research Foundation, Inc. | Determining viral load in double negative t cells |
CA2362126C (en) * | 1999-02-03 | 2017-01-17 | Amgen Inc. | B7rp-1 polypeptides |
CA2360664C (en) | 1999-02-04 | 2012-04-17 | Shoshana Merchav | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
EP1227321A1 (en) * | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
WO2009003492A1 (en) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US8076452B2 (en) | 2002-03-01 | 2011-12-13 | Erdmann Volker A | Streptavidin-binding peptide |
US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
WO2003090781A1 (en) | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
JP2006501449A (ja) | 2002-09-27 | 2006-01-12 | ザ ジェネラル ホスピタル コーポレーション | 細胞分離のためのマイクロ流体デバイスおよびその使用 |
US7795024B2 (en) | 2003-05-02 | 2010-09-14 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
DK1623017T3 (da) * | 2003-05-08 | 2011-01-10 | Life Technologies Corp | Frembringelse og isolering af antigenspecifikke T-celler |
AU2004292131A1 (en) | 2003-11-20 | 2005-06-02 | Biosensor Applications Sweden (Publ) | Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture |
SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
EP1766400B1 (en) | 2004-06-03 | 2009-04-15 | Meso Scale Technologies, LLC | Methods for conducting whole blood assays |
DK1800136T3 (da) | 2004-10-15 | 2012-03-26 | Danisco Us Inc | Kompetitiv differentiel screening |
WO2006058226A2 (en) * | 2004-11-24 | 2006-06-01 | The Trustees Of Boston University | Modified dimeric streptavidins and uses thereof |
US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
US7704708B2 (en) * | 2006-02-13 | 2010-04-27 | Uti Limited Partnership | Monomeric streptavidin muteins |
US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
WO2007117602A2 (en) | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation and use of human regulatory t cells |
US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
CN102850435B (zh) | 2006-10-17 | 2016-02-17 | 肿瘤疗法科学股份有限公司 | 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 |
US8043822B2 (en) | 2006-11-02 | 2011-10-25 | Kyowa Medex Co., Ltd. | Method of immunoassaying a component to be measured |
CN101622340A (zh) | 2006-11-15 | 2010-01-06 | 茵维特罗根戴纳股份公司 | 生物素化合物与支持物可逆结合的方法 |
US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
WO2008118476A2 (en) * | 2007-03-26 | 2008-10-02 | Codon Devices, Inc. | Cell surface display, screening and production of proteins of interest |
EP2193199B1 (en) | 2007-08-20 | 2013-11-06 | Nextera AS | Pvii phage display |
DK2433713T3 (en) | 2007-12-07 | 2017-09-25 | Miltenyi Biotec Gmbh | CELL PROCESSING SYSTEMS AND PROCEDURES |
KR20200091961A (ko) | 2008-01-18 | 2020-07-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
JP2011510653A (ja) | 2008-01-29 | 2011-04-07 | フレッド ハッチンソン キャンサー リサーチ センター | CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定 |
CN101446576B (zh) | 2008-12-29 | 2011-06-22 | 江苏省苏微微生物研究有限公司 | 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法 |
WO2010080032A2 (en) | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
US20120214187A1 (en) * | 2009-11-02 | 2012-08-23 | Ffina Biolutions, Llc | Method for Enhancing the Sensitivity of Antibody Based Assays |
US20120321665A1 (en) * | 2009-12-14 | 2012-12-20 | Benaroya Research Institute At Virginia Mason | Compositions and methods for treating airway inflammatory diseases |
EP2363501A1 (en) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
US9678061B2 (en) | 2010-08-06 | 2017-06-13 | Ludwig-Maximilians-Universität München | Identification of T cell target antigens |
WO2012058627A2 (en) | 2010-10-29 | 2012-05-03 | Miqin Zhang | Pre-targeted nanoparticle system and method for labeling biological particles |
NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
EP3418295B1 (en) * | 2011-07-18 | 2020-09-02 | IBA GmbH | Method of reversibly staining a target cell |
WO2013038272A2 (en) | 2011-09-13 | 2013-03-21 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
US10228312B2 (en) | 2012-02-23 | 2019-03-12 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
UA114108C2 (uk) * | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
CN112375846A (zh) | 2012-07-13 | 2021-02-19 | 宾夕法尼亚大学董事会 | 评估用于施用的转导t细胞的适用性的方法 |
IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
JP6475630B2 (ja) | 2012-11-16 | 2019-02-27 | イーベーアー ゲーエムベーハー | ストレプトアビジン突然変異タンパク質およびそれらを使用する方法 |
CN103305464B (zh) | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
PL3083671T3 (pl) | 2013-12-20 | 2021-03-22 | Fred Hutchinson Cancer Center | Znakowane chimeryczne cząsteczki efektorowe i ich receptory |
MX2016013239A (es) | 2014-04-07 | 2017-05-03 | Novartis Ag | Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19. |
SG11201608557UA (en) * | 2014-04-16 | 2016-11-29 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
ES2759260T3 (es) | 2014-04-23 | 2020-05-08 | Juno Therapeutics Inc | Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva |
KR20160145162A (ko) | 2014-04-24 | 2016-12-19 | 밀테니 비오텍 게앰베하 | 유전적으로 변형된 t 세포의 자동화 생성 방법 |
SI3134095T1 (sl) | 2014-04-25 | 2020-08-31 | Bluebird Bio, Inc. | Izboljšani postopki za izdelavo adoptivnih celičnih terapij |
US11150239B2 (en) * | 2014-04-30 | 2021-10-19 | Iba Lifesciences Gmbh | Method of isolating a target cell |
DK3280729T3 (da) | 2015-04-08 | 2022-07-25 | Novartis Ag | Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
BR112018008111A2 (pt) | 2015-10-22 | 2018-11-06 | Juno Therapeutics Gmbh | métodos, kits, agentes e aparelhos para transdução |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
WO2017096329A1 (en) | 2015-12-03 | 2017-06-08 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
MA49288A (fr) | 2017-04-27 | 2020-03-04 | Juno Therapeutics Gmbh | Reactifs particulaires oligomères et leurs méthodes d'utilisation |
JP2021533746A (ja) | 2018-08-09 | 2021-12-09 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞およびその組成物を生成するための方法 |
JP2022512872A (ja) | 2018-10-31 | 2022-02-07 | ジュノ セラピューティクス ゲーエムベーハー | 細胞の選択および刺激のための方法ならびにそのための装置 |
-
2015
- 2015-04-16 SG SG11201608557UA patent/SG11201608557UA/en unknown
- 2015-04-16 CA CA3176848A patent/CA3176848A1/en active Pending
- 2015-04-16 PT PT157206202T patent/PT3132247T/pt unknown
- 2015-04-16 IL IL293587A patent/IL293587A/en unknown
- 2015-04-16 IL IL280738A patent/IL280738B/en unknown
- 2015-04-16 CA CA2945889A patent/CA2945889C/en active Active
- 2015-04-16 EP EP21191440.3A patent/EP3988920A1/en active Pending
- 2015-04-16 EP EP15720620.2A patent/EP3132247B1/en active Active
- 2015-04-16 AU AU2015248786A patent/AU2015248786B2/en active Active
- 2015-04-16 LT LTEPPCT/EP2015/058339T patent/LT3132247T/lt unknown
- 2015-04-16 PL PL15720620T patent/PL3132247T3/pl unknown
- 2015-04-16 RU RU2016144724A patent/RU2735640C9/ru active
- 2015-04-16 ES ES15720620T patent/ES2892927T3/es active Active
- 2015-04-16 WO PCT/EP2015/058339 patent/WO2015158868A2/en active Application Filing
- 2015-04-16 KR KR1020227036837A patent/KR20220150988A/ko not_active Application Discontinuation
- 2015-04-16 CN CN202310417528.8A patent/CN116656605A/zh active Pending
- 2015-04-16 BR BR112016024072-3A patent/BR112016024072B1/pt active IP Right Grant
- 2015-04-16 CN CN201580032543.4A patent/CN106414724A/zh active Pending
- 2015-04-16 KR KR1020167031915A patent/KR102459384B1/ko active IP Right Grant
- 2015-04-16 JP JP2017505717A patent/JP6696969B2/ja active Active
- 2015-04-16 HU HUE15720620A patent/HUE056852T2/hu unknown
- 2015-04-16 US US15/304,045 patent/US11274278B2/en active Active
- 2015-04-16 CN CN202010423347.2A patent/CN111961647A/zh active Pending
- 2015-04-16 MY MYPI2016703777A patent/MY184699A/en unknown
- 2015-04-16 SG SG10201808491UA patent/SG10201808491UA/en unknown
- 2015-04-16 MX MX2016013493A patent/MX2016013493A/es unknown
- 2015-04-16 SI SI201531727T patent/SI3132247T1/sl unknown
- 2015-04-16 RU RU2020133435A patent/RU2020133435A/ru unknown
- 2015-04-16 RS RS20211143A patent/RS62471B1/sr unknown
- 2015-04-16 DK DK15720620.2T patent/DK3132247T3/da active
-
2016
- 2016-10-11 PH PH12016502017A patent/PH12016502017B1/en unknown
- 2016-10-13 IL IL248360A patent/IL248360B/en active IP Right Grant
- 2016-10-13 MX MX2020014089A patent/MX2020014089A/es unknown
- 2016-10-16 SA SA516380090A patent/SA516380090B1/ar unknown
-
2020
- 2020-04-23 JP JP2020076705A patent/JP2020124210A/ja active Pending
- 2020-07-01 PH PH12020551028A patent/PH12020551028A1/en unknown
-
2021
- 2021-09-13 HR HRP20211430TT patent/HRP20211430T1/hr unknown
- 2021-11-02 CY CY20211100943T patent/CY1124717T1/el unknown
-
2022
- 2022-01-27 AU AU2022200527A patent/AU2022200527A1/en active Pending
- 2022-03-11 US US17/693,292 patent/US20220195388A1/en active Pending
-
2023
- 2023-02-20 JP JP2023024443A patent/JP2023062124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124717T1 (el) | Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων | |
CY1123220T1 (el) | Πρωτεϊνες συνδεσης anti-lag-3 | |
BR112014025384A8 (pt) | método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
BR112018010681A8 (pt) | método para modificar um sítio alvejado, complexo de enzima de modificação de ácido nucleico, e, ácido nucleico. | |
BR112017022329A2 (pt) | métodos para detectar aglutinação e composições para uso na prática do mesmo | |
SA518400078B1 (ar) | مصفوفة مولد ضد | |
PH12014502581B1 (en) | Aptamer-based multiplexed assays | |
BR112014018995A2 (pt) | Sistemas para executar ensaio automatizado | |
CL2017002604A1 (es) | Sondas duales silenciadoras | |
EA201692157A1 (ru) | Синтез двухцепочечных нуклеиновых кислот | |
BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
EP3654036A3 (en) | Stomach cancer biomarker and detection method | |
BR112016008970A2 (pt) | Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
TR201907737T4 (tr) | Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi. | |
AU2013252445A8 (en) | Assays, methods and apparatus for assessing RNA disruption | |
CY1123180T1 (el) | Συστημα ανιχνευσης που αξιοποιει αλυσιδωτη αντιδραση πολυμερασης | |
BR112019006862A2 (pt) | dispositivo de análise e método para testagem de uma amostra | |
GB2542576A (en) | Method and kit of detecting the absence of micro-oranisms | |
EP4282961A3 (en) | Compositions and methods for the detection and analysis of mycobacterium tuberculosis | |
EP4242663A3 (en) | Methods for characterizing compositions comprising peanut antigens | |
BR112017002575A2 (pt) | método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo |